Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Despite Merck KGaA’s lupus drug failing to prove itself against one form of the autoimmune disease, the German drugmaker has ...

Shares fell after the company cut its full-year guidance on the back of challenging macroeconomic conditions and ...

By Ludwig Burger FRANKFURT (Reuters) -German pharmaceutical and specialty materials group Merck KGaA on Thursday guided more ...

The Trump administration is already gearing up for another round of Medicare drug price negotiations, while OpenAI launched a ...

Pfizer beats EPS estimates for the 12th quarter. Explore PFE's oncology success, cost-cutting impact, and why it's rated a ...

Phase 3 clinical trial of BNC-210 in social anxiety disorder on track for topline readout in Q3 2025α7 nicotinic ...

We recently published a list of the 20 Best Dividend Growth Stocks with High Yields. In this article, we are going to take a ...

Merck & Co – known as MSD outside the US and Canada – has received approval from the Medicines and Healthcare products ...

People need healthcare products and services regardless of what's happening with the economy. Which healthcare stocks could ...

Merck KGaA, the German science and technology group, trimmed its profit forecast, citing a weakening US dollar and ...

Merck (MRK) stock gains as its bestselling drug, Keytruda, as part of a combination regimen, succeeds in a Phase 3 trial for ...